STOCK TITAN

Boston Scientific (NYSE: BSX) SVP nets shares after RSU vesting

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Boston Scientific SVP Emily Woodworth reported several equity transactions involving restricted stock units and common stock. On February 13–16, 2026, she exercised restricted stock units that convert into an equal number of Boston Scientific common shares, with individual transactions including 1,413, 661, and 637 units. Corresponding common stock entries show the same share amounts acquired at a stated price of $0.0000 per share, reflecting non-cash derivative exercises. Additional common stock entries coded “F” cover 690, 296, and 283 shares delivered at $74.73 per share to satisfy tax liabilities rather than open-market sales. Footnotes state that each restricted stock unit represents a commitment to issue one share of common stock, generally in four equal annual installments beginning on specific grant anniversaries.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Woodworth Emily

(Last) (First) (Middle)
300 BOSTON SCIENTIFIC WAY

(Street)
MARLBOROUGH MA 01752-1234

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, Global Controller and CAO
3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/13/2026 M 1,413 A $0.0000(1) 2,364 D
Common Stock 02/13/2026 F 690 D $74.73 1,674 D
Common Stock 02/14/2026 M 661 A $0.0000(1) 2,335 D
Common Stock 02/14/2026 F 296 D $74.73 2,039 D
Common Stock 02/16/2026 M 637 A $0.0000(1) 2,676 D
Common Stock 02/16/2026 F 283 D $74.73 2,393 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 02/13/2026 M 1,413 (2) 02/13/2029(2) Common Stock 1,413 $0.0000 4,239 D
Restricted Stock Units (1) 02/14/2026 M 661 (3) 02/14/2027(3) Common Stock 661 $0.0000 661 D
Restricted Stock Units (1) 02/16/2026 M 637 (4) 02/16/2026(4) Common Stock 637 $0.0000 0.0000 D
Explanation of Responses:
1. Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
2. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.
3. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.
4. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.
/s/ Susan Thompson, Attorney-in-Fact 02/18/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Boston Scientific (BSX) report for Emily Woodworth?

Boston Scientific reported that SVP Emily Woodworth exercised restricted stock units into common stock and had some shares withheld to cover tax obligations. The transactions occurred over February 13–16, 2026 and involved both derivative and non-derivative securities.

How many Boston Scientific (BSX) restricted stock units did the SVP convert?

The filing shows Woodworth exercised restricted stock units in separate transactions of 1,413, 661, and 637 units. Each restricted stock unit represents a commitment to issue one share of Boston Scientific common stock, according to the footnotes included in the report.

Were any of Emily Woodworth’s Boston Scientific (BSX) transactions open-market sales?

The transactions coded “F” in the filing reflect shares delivered to pay tax liabilities, not open-market sales. These covered 690, 296, and 283 common shares at a stated price of $74.73 per share, consistent with tax-withholding dispositions.

What do the restricted stock unit footnotes mean for Boston Scientific (BSX) shares?

Footnotes explain that each restricted stock unit equals one share of Boston Scientific common stock. Shares are scheduled to be issued in four equal annual installments beginning on specific grant anniversaries, such as February 13, 2026, depending on the original grant date.

What role does Emily Woodworth hold at Boston Scientific (BSX)?

The reporting person, Emily Woodworth, is identified as SVP, Global Controller and CAO of Boston Scientific. Her position as a senior officer requires reporting these equity transactions on Form 4 to provide transparency about her holdings in the company.

How did these Boston Scientific (BSX) transactions affect Woodworth’s direct ownership?

The filing shows her direct common stock ownership changing with each transaction, with share balances reported after every entry. For example, one line shows 2,393 common shares directly owned following a tax-withholding disposition coded “F” on February 16, 2026.
Boston Scien Cp

NYSE:BSX

BSX Rankings

BSX Latest News

BSX Latest SEC Filings

BSX Stock Data

113.14B
1.48B
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MARLBOROUGH